Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor

Blood

Volumn 98, Issue 6, 2001, Pages 1942-1948

  Monneret, Guillaume ^a,b   Gravel, Sylvie ^a,b   Diamond, Michael ^a,b   Rokach, Joshua ^a,b   Powell, William S ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b Florida Institute of Technology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

13,14 DIHYDRO 15 OXOPROSTAGLANDIN D2; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 5 (6 CARBOXYHEXYL) 1 (3 CYCLOHEXYL 3 HYDROXYPROPYL)HYDANTOIN; ADENYLATE CYCLASE; CARBACYCLIN; CD11B ANTIGEN; CHEMOATTRACTANT; CYCLIC AMP; L SELECTIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN RECEPTOR; PROSTANOID; UNCLASSIFIED DRUG; 3 BENZYL 5 (6 CARBOXYHEXYL) 1 (2 CYCLOHEXYL 2 HYDROXYETHYLAMINO)HYDANTOIN; ACTIN; CHEMOTACTIC FACTOR; HYDANTOIN DERIVATIVE; IMMUNOGLOBULIN RECEPTOR; PROSTAGLANDIN; PROSTAGLANDIN D2 RECEPTOR;

ACTIN POLYMERIZATION; ANTIGEN EXPRESSION; ARTICLE; ASTHMA; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; DRUG MECHANISM; EOSINOPHIL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; BIOLOGICAL MODEL; BIOSYNTHESIS; CELL CULTURE; DOSE RESPONSE; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS;

ACTINS; CELLS, CULTURED; CHEMOTACTIC FACTORS; CHEMOTAXIS, LEUKOCYTE; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; EOSINOPHILS; HUMANS; HYDANTOINS; L-SELECTIN; MACROPHAGE-1 ANTIGEN; MODELS, BIOLOGICAL; NEUTROPHILS; PROSTAGLANDIN D2; PROSTAGLANDINS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN;

EID: 0035883174     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.6.1942     Document Type: Article

References (53)

1. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999;79:1193-1226.
2. 2 receptors in human platelets. J Pharmacol Exp Ther. 1979;210:134-140.
3. Norel X, Walch L, Labat C, Gascard JP, Dulmet E, Brink C. Prostanoid receptors involved in the relaxation of human bronchial preparations. Br J Pharmacol. 1999;126:867-872.
4. Walch L, Labat C, Gascard JP, de Montpreville V, Brink C, Norel X. Prostanoid receptors involved in the relaxation of human pulmonary vessels. Br J Pharmacol. 1999;126:859-866.
5. 2 and sleep regulation. Biochim Biophys Acta. 1999;1436:606-615.
6. Eguchi N, Minami T, Shirafuji N, et al. Lack of tactile pain (allodynia) in lipocalin-type prostaglandin D synthase-deficient mice. Proc Natl Acad Sci U S A. 1999;96:726-730.
7. Urade Y, Ujihara M, Horiguchi Y, et al. Mast cells contain spleen-type prostaglandin D synthetase. J Biol Chem. 1990;265:371-375.
8. 2 production is likely antigen-presenting cells: localization of glutathione-requiring prostaglandin D synthetase in histiocytes, dendritic, and Kupffer cells in various rat tissues. J Immunol. 1989;143:2982-2989.
9. 2 by human helper T cell subsets. J Immunol. 2000;164:2277-2280.
10. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma: from bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000;161:1720-1745.
11. 2 generation after activation of rat and human mast cells with anti-IgE. J Immunol. 1982;129:1627-1631.
12. 2 into human airways during acute antigen challenge. N Engl J Med. 1986;315:800-804.
13. 2 as a mediator of allergic asthma. Science. 2000;287:2013-2017.
14. Giembycz MA, Lindsay MA. Pharmacology of the eosinophil. Pharmacol Rev. 1999;51:213-340.
15. 2) on circulating eosinophils. Prostaglandins Leukot Med. 1984;15:387-397.
16. 2 causes accumulation of eosinophils in the lumen of the dog trachea. J Appl Physiol. 1989;67:959-962.
17. 2 and histamine activate human eosinophils. J Immunol. 1992;148:3536-3542.
18. 4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol. 1996;118:1727-1735.
19. Kita H, Abu-Ghazaleh RI, Gleich GJ, Abraham RT. Regulation of Ig-induced eosinophil degranulation by adenosine 3′,5′-cyclic monophosphate. J Immunol. 1991;146:2712-2718.
20. Khanapure SP, Shi XX, Powell WS, Rokach J. Total synthesis of potent proinflammatory 5-oxo-ETE and its 6,7-dihydro biotransformation product. J Organic Chem. 1998;63:337-342.
21. Böyum A. Isolation of mononuclear cells and granulocytes from human blood: isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77-89.
22. Hansel TT, De Vries IJ, Iff T, et al. An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J Immunol Methods. 1991;145:105-110.
23. Powell WS, Chung D, Gravel S. 5-Oxo-6,8,11,14-eicosatetraenoic acid is a potent stimulator of human eosinophil migration. J Immunol. 1995;154:4123-4132.
24. Kay AB. Studies on eosinophil leucocyte migration, II: factors specifically chemotactic for eosinophils and neutrophils generated from guinea-pig serum by antigen-antibody complexes. Clin Exp Immunol. 1970;7:723-737.
25. Howard TH, Oresajo CO. The kinetics of chemotactic peptide-induced change in F-actin content, F-actin distribution, and the shape of neutrophils. J Cell Biol. 1985;101:1078-1085.
26. Powell WS, Ahmed S, Gravel S, Rokach J. Eotaxin and RANTES enhance 5-oxo-6,8,11,14-eicosatetraenoic acid-induced eosinophil chemotaxis. J Allergy Clin Immunol. 2001;107:272-278.
27. Powell WS, Gravel S, Khanapure SP, Rokach J. Biological inactivation of 5-oxo-6,8,11,14-eicosatetraenoic acid by human platelets. Blood. 1999;93:1086-1096.
28. Powell WS, Gravel S, MacLeod RJ, Mills E, Hashefi M. Stimulation of human neutrophils by 5-oxo-6,8,11,14-eicosatetraenoic acid by a mechanism independent of the leukotriene B4 receptor. J Biol Chem. 1993;268:9280-9286.
29. Barnes PJ, Chung KF, Page CP. Inflammatory mediators of asthma: an update. Pharmacol Rev. 1998;50:515-596.
30. Rothenberg ME. Eosinophilia. N Engl J Med. 1998;338:1592-1600.
31. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997;122:217-224.
32. Wright DH, Metters KM, Abramovitz M, Ford-Hutchinson AW. Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br J Pharmacol. 1998;123:1317-1324.
33. McKenniff M, Rodger IW, Norman P, Gardiner PJ. Characterisation of receptors mediating the contractile effects of prostanoids in guinea-pig and human airways. Eur J Pharmacol. 1988;153:149-159.
34. Coleman RA, Sheldrick RL. Prostanoid-induced contraction of human bronchial smooth muscle is mediated by TP-receptors. Br J Pharmacol. 1989;96:688-692.
35. Ebisawa M, Bochner BS, Georas SN, Schleimer RP. Eosinophil transendothelial migration induced by cytokines, I: role of endothelial and eosinophil adhesion molecules in IL-1 beta-induced transendothelial migration. J Immunol. 1992;149:4021-4028.
36. Preece G, Murphy G, Ager A. Metalloproteinase-mediated regulation of L-selectin levels on leucocytes. J Biol Chem. 1996;271:11634-11640.
37. Powell WS, Gravel S, Halwani F. 5-Oxo-6,8,11,14-eicosatetraenoic acid is a potent stimulator of L-selectin shedding, surface expression of CD11b, actin polymerization, and calcium mobilization in human eosinophils. Am J Respir Cell Mol Biol. 1999;20:163-170.
38. 2 receptors. Prostaglandins. 1983;25:13-28.
39. Giles H, Leff P, Bolofo ML, Kelly MG, Robertson AD. The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist. Br J Pharmacol. 1989;96:291-300.
40. Dent G, Giembycz MA, Rabe KF, Barnes PJ. Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors. Br J Pharmacol. 1991;103:1339-1346.
41. Butchers PR, Vardey CJ. The effect of prostanoids on the function of human eosinophils. Agents Actions Suppl. 1990;31:103-112.
42. Santamaria LF, Palacios JM, Beleta J. Inhibition of eotaxin-mediated human eosinophil activation and migration by the selective cyclic nucleotide phosphodiesterase type 4 inhibitor rolipram. Br J Pharmacol. 1997;121:1150-1154.
43. Berends C, Dijkhuizen B, de Monchy JG, Dubois AE, Gerritsen J, Kauffman HF. Inhibition of PAF-induced expression of CD11b and shedding of L-selectin on human neutrophils and eosinophils by the type IV selective PDE inhibitor, rolipram. Eur Respir J. 1997;10:1000-1007.
44. Kaneko T, Alvarez R, Ueki IF, Nadel JA. Elevated intracellular cyclic AMP inhibits chemotaxis in human eosinophils. Cell Signal. 1995;7:527-534.
45. Ney P, Schrör K. PGD2 and its mimetic ZK 110.841 are potent inhibitors of receptor-mediated activation of human neutrophils. Eicosanoids. 1991;4:21-28.
46. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med. 1999;5:698-701.
47. Willoughby DA, Moore AR, Colville-Nash PR. Cyclopentenone prostaglandins: new allies in the war on inflammation. Nat Med. 2000;6:137-138.
48. 2 and its analogues. Br J Pharmacol. 1985;85:367-375.
49. 2α receptor in bovine corpora lutea. Eur J Biochem. 1975;56:73-77.
50. Rangachari PK, Betti PA, Prior ET, Roberts LJ. Effects of a selective DP receptor agonist (BW 245C) and antagonist (BW A868C) on the canine colonic epithelium: an argument for a different DP receptor? J Pharmacol Exp Ther. 1995;275:611-617.
51. 2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med. 2001;193:255-261.
52. Nagata K, Tanaka K, Ogawa K, et al. Selective expression of a novel surface molecule by human TH2 cells in vivo. J Immunol. 1999;162:1278-1286.
53. Nagata K, Hirai H, Tanaka K, et al. CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett. 1999;459:195-199.